A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer

Trial Profile

A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Capecitabine (Primary) ; Aromatase inhibitors; Cyclophosphamide; Docetaxel; Doxorubicin; Tamoxifen; Trastuzumab
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2011 Planned End Date changed from 1 Feb 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Pooled analysis results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top